The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
The consideration for the medicines in India is valued at Rs 180.48 crore
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Subscribe To Our Newsletter & Stay Updated
